Artal Group S.A. increased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 66.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 50,000 shares of the biopharmaceutical company’s stock after buying an additional 20,000 shares during the period. Artal Group S.A. owned 0.12% of Ultragenyx Pharmaceutical worth $3,106,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. New York State Common Retirement Fund raised its stake in Ultragenyx Pharmaceutical by 7.7% during the second quarter. New York State Common Retirement Fund now owns 70,036 shares of the biopharmaceutical company’s stock worth $4,350,000 after buying an additional 4,987 shares during the last quarter. Amalgamated Bank raised its stake in Ultragenyx Pharmaceutical by 7.6% during the second quarter. Amalgamated Bank now owns 4,980 shares of the biopharmaceutical company’s stock worth $309,000 after buying an additional 352 shares during the last quarter. BlackRock Inc. raised its stake in Ultragenyx Pharmaceutical by 10.4% during the second quarter. BlackRock Inc. now owns 3,497,591 shares of the biopharmaceutical company’s stock worth $217,237,000 after buying an additional 330,911 shares during the last quarter. Nationwide Fund Advisors raised its stake in Ultragenyx Pharmaceutical by 24.2% during the second quarter. Nationwide Fund Advisors now owns 60,023 shares of the biopharmaceutical company’s stock worth $3,728,000 after buying an additional 11,685 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its stake in Ultragenyx Pharmaceutical by 7.6% during the second quarter. Ameriprise Financial Inc. now owns 101,774 shares of the biopharmaceutical company’s stock worth $6,320,000 after buying an additional 7,229 shares during the last quarter. 96.07% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Inc. (RARE) traded down 1.92% on Tuesday, reaching $51.97. 68,249 shares of the company’s stock were exchanged. The company’s market cap is $2.21 billion. Ultragenyx Pharmaceutical Inc. has a 52-week low of $49.56 and a 52-week high of $91.35. The firm’s 50 day moving average price is $56.92 and its 200 day moving average price is $63.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.73) by $0.01. During the same quarter in the prior year, the business earned ($1.46) EPS. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.21) earnings per share for the current year.

In other news, CEO Emil D. Kakkis acquired 7,500 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, August 28th. The stock was acquired at an average cost of $52.52 per share, for a total transaction of $393,900.00. Following the purchase, the chief executive officer now owns 430,569 shares in the company, valued at $22,613,483.88. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.20% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Artal Group S.A. Has $3.11 Million Position in Ultragenyx Pharmaceutical Inc. (RARE)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/19/artal-group-s-a-has-3-11-million-position-in-ultragenyx-pharmaceutical-inc-rare.html.

RARE has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Canaccord Genuity set a $98.00 target price on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Friday, July 28th. BidaskClub downgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Jefferies Group LLC reissued a “hold” rating and set a $68.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 14th. Finally, J P Morgan Chase & Co set a $76.00 target price on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, August 23rd. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $71.65.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.